Updated from 1:19 p.m. EDT
PacifiCare Health Systems
( PHS) were among the best-performing health-related stocks Friday, rising 10.5% after the company posted first-quarter results that topped forecasts and raised its full-year earnings outlook.
The health plan provider earned $85.7 million, or 89 cents a share, on sales of $3.44 billion. Analysts surveyed by First Call were expecting earnings of 88 cents a share on sales of $3.42 billion. A year ago, the company earned $67 million, or 71 cents a share, on sales of $2.96 billion.
Year-over-year earnings gains were primarily driven by an increase in senior membership, the acquisition of American Medical Security Group and by growth in mail service volume at the company's Prescription Solutions unit, which performs pharmacy benefit management services. Looking ahead, PacifiCare raised its 2005 earnings guidance, saying that it now expects $3.70 to $3.85 a share. Analysts are expecting earnings of $3.77 a share. Shares traded up $5.66 to $59.76.
rose modestly after the company posted third-quarter earnings and sales that topped forecasts. The medical supplier posted earnings from continuing operations of $367.8 million, or 84 cents a share, on sales of $19.1 billion. Excluding items amounting to $44.5 million, the company would have earned 94 cents a share. Analysts were expecting earnings of 89 cents a share on sales of $18.7 billion. A year ago, the company earned $430.1 million, or 98 cents a share, on sales of $16.4 billion. Looking ahead, Cardinal backed its 2005 earnings guidance of $3.10 to $3.20 a share. Analysts are looking for earnings of $3.16 a share on sales of $74.4 billion. Shares traded up 56 cents, or 1%, to $55.57.
rose 9.9% after the small biotech firm announced an antibody-drug conjugate collaboration with
( MEDI). The arrangement calls for MedImmune to pay Seattle Genetics an upfront fee of $2 million for the rights to use the company's antibody-drug conjugate technology for use in targeting a single tumor that MedImmune has selected. MedImmune, in addition to paying the upfront fee of $2 million, also agreed to make process-dependent milestone payments and pay royalties on sales of any resulting ADC products. Shares traded up 36 cents to $4.
rose 5.1% after the company posted a big jump in first-quarter earnings and sales. The medical information company posted earnings of $9.8 million, or 3 cents a share, on sales of $303.9 million. Earnings before taxes, noncash and other items totaled $38.8 million, or 12 cents a share. Analysts were expecting earnings of 11 cents a share on sales of $300 million. A year ago the company posted earnings before taxes of $28.2 million, or 9 cents a share, on sales of $271.2 million. Looking ahead, WebMD raised its 2005 earnings guidance to 54 cents to 60 cents a share on sales of $1.26 billion to $1.3 billion. Analysts are expecting earnings of 49 cents a share on sales of $1.24 billion. Shares traded up 46 cents to $9.47.
( DRTE) rose 8.9% after the company posted first-quarter sales that were ahead of expectations. Excluding items, the company posted adjusted earnings of $5.1 million, or 12 cents a share -- in line with expectations -- on sales of $99.4 million. Analysts were expecting sales of $98.8 million. A year ago, the provider of software and services to the pharmaceutical industry earned $6.3 million, or 15 cents a share, on sales of $95.1 million. Looking ahead, Dendrite backed its first-half earnings guidance of 36 cents to 38 cents a share on sales of $211 million to $215 million. That's in line with analysts' expectations. Shares traded up $1.26 to $15.42.
Other health-care volume movers included
, up 82 cents to $5.51;
, up 48 cents to $27.17;
( AMLN), down $1.18 to $17;
( MATK), up $5.78 to $38.29;
, up 86 cents to $58.21;
, up 11 cents to $33.90;
Johnson & Johnson
, up 97 cents to $68.63;
( DNA), up 92 cents to $70.94;
, up 37 cents to $37.11; and
( SGP), up 40 cents to $20.87.